C12orf57 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the poorly characterized gene C12orf57. This product provides a heterogeneous pool of Jurkat cells harboring frameshift mutations across the C12orf57 locus, resulting in disruption of endogenous protein expression. The polyclonal format avoids clonal selection artifacts and preserves population-level complexity, making it suitable for investigating the functional consequences of C12orf57 deficiency in T-cell biology. Researchers can employ this model to interrogate the gene??s role in cell cycle progression, apoptosis, and T-cell receptor signaling without the confounding effects of monoclonal adaptation.
Jurkat cells, the host cell line, are a widely utilized immortalized T lymphoblastoid model originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. These suspension cells exhibit constitutive activation of T-cell signaling pathways and serve as a cornerstone for studying T-cell receptor transduction, IL-2 production, and leukemogenesis. Their robust growth and transfection efficiency make them an ideal chassis for CRISPR-mediated gene disruption, enabling rapid generation of knockout pools for functional genomics screening. The leukemic origin of Jurkat cells also renders them particularly relevant for investigating oncogenic signaling and tumor suppressor functions.
The molecular function of C12orf57 remains elusive, though bioinformatic predictions suggest involvement in intracellular signaling or protein?Cprotein interactions. Homozygous loss-of-function mutations in C12orf57 are causally linked to Temtamy syndrome, a rare neurodevelopmental disorder, indicating an essential role in developmental processes. In the Jurkat context, C12orf57 may intersect with pathways governing cell cycle checkpoints or apoptotic machinery, as inferred from phenotypic studies of Temtamy syndrome patient cells. However, no direct upstream regulators, downstream effectors, or binding partners have been conclusively identified. The uncharacterized nature of C12orf57 positions this knockout pool as a discovery tool to illuminate its interactome and pathway affiliations through unbiased proteomic or genetic screens.
Disruption of C12orf57 in Jurkat cells offers a unique platform to dissect its contribution to T lymphoblast physiology. Because Jurkat cells retain core T-cell signaling modules, phenotypic readouts such as activation-induced apoptosis, NFAT translocation, or cytokine secretion can be correlated with C12orf57 status. The polyclonal architecture captures a spectrum of knockout efficiencies and off-target effects, mimicking the genetic variability encountered in primary cell populations. This model is especially valuable for Temtamy syndrome research, as it enables comparison of neuronal and lymphoid cell types to identify tissue-specific functions of C12orf57.
Typical research applications of this product include functional annotation of C12orf57 through proliferation and apoptosis assays, investigation of Temtamy syndrome pathomechanisms in an accessible cell-based system, and genome-wide CRISPR modifier screens to identify synthetic lethal interactions. Western blotting and RT-qPCR confirm protein depletion and transcript-level changes, while flow cytometry facilitates cell cycle and apoptosis analysis. The knockout pool also supports pharmacological profiling to assess how C12orf57 loss alters drug sensitivity. For further information or to discuss custom projects, please contact Ascent Research.
